Sign In
Buy NVS
$148.93
+1.85 (+1.26%)
At Close: Jun 22, 2026
Park Avenue Securities LLC Trims Stake in Novartis AG $NVS
05:02am, Sunday, 22'nd Mar 2026
Park Avenue Securities LLC lowered its position in Novartis AG (NYSE: NVS) by 8.2% in the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 48,5
Novartis Strikes $3B Oncology Deal for Breast Cancer Asset
03:55pm, Friday, 20'th Mar 2026
NVS bets $2B upfront on SNV4818 to expand precision oncology in breast cancer, targeting a large mutation-driven market and boosting long-term pipeline growth.
US FDA flags seizure risk with certain Parkinson's drugs, seeks label warnings
12:11pm, Friday, 20'th Mar 2026
The U.S. Food and Drug Administration said on Friday it has notified manufacturers of certain Parkinson's disease treatments to update their prescribing information with a new warning about a po
Novartis Places $3 Billion Bet On Early Cancer Drug
07:25am, Friday, 20'th Mar 2026
Novartis (NVS) is leaning further into cancer treatments, agreeing to buy an experimental breast cancer drug from Synnovation Therapeutics in a deal worth up to
Novartis to Buy Breast-Cancer Drug From Synnovation for Up to $3 Billion
02:33am, Friday, 20'th Mar 2026
SNV4818 is being evaluated in an early and mid-stage study for breast cancer and other advanced solid tumors, Novartis said.
Novartis to buy breast cancer drug candidate from Synnovation
02:25am, Friday, 20'th Mar 2026
Novartis said on Friday it agreed to acquire breast cancer drug candidate SNV4818 from Synnovation Therapeutics for $2 billion upfront and up to $1 billion contingent on further d
Novartis to Acquire Synnovation Therapeutics' Pan-Mutant Selective PI3Kα Inhibitor Program
02:05am, Friday, 20'th Mar 2026
WILMINGTON, Del.--(BUSINESS WIRE)--Synnovation Therapeutics, LLC (“Synnovation”), a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncol
Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline
02:00am, Friday, 20'th Mar 2026
Basel, March 20, 2026 – Novartis today announced that it has entered into an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a pan-mutant‑selective PI3Kα inhibitor, exploring a n
TrumpRx lists many medicines at prices higher than paid in UK
02:23pm, Wednesday, 18'th Mar 2026
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those
Big drugmakers must face US overcharge claims on medications for low-income patients
02:32pm, Tuesday, 17'th Mar 2026
A U.S. appeals court on Tuesday revived a whistleblower lawsuit accusing four large drugmakers of defrauding the federal and state governments out of hundreds of millions of dollars by overcharg
FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for Adolescents
10:42am, Monday, 16'th Mar 2026
Novartis wins FDA nod to expand Cosentyx use to teens with hidradenitis suppurativa, making it the only IL-17A inhibitor for this group.
Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients
09:42am, Monday, 16'th Mar 2026
FDA approves Novartis' Cosentyx for moderate to severe hidradenitis suppurativa in patients aged 12 and older, expanding treatment options.
Market Today: Oil Spike Hits Stocks; Adobe, Amazon in Focus
05:34pm, Friday, 13'th Mar 2026
Stock News Stocks slide as oil tops $100: The S&P 500 fell 0.61% to a 2026 low and notched a third straight weekly decline as Brent closed above $100 and WTI ne
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
01:35pm, Friday, 13'th Mar 2026
Basel, March 13, 2026 – Novartis announced today that Cosentyx® (secukinumab) received US Food and Drug Administration (FDA) approval for treating pediatric patients 12 years and older with mod
First Look: Oil at $100, Fed Cut Odds Fade; LCID, RIVN
06:37am, Friday, 13'th Mar 2026
Stock News Futures steady after selloff: SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA) and Invesco QQQ Trust (QQQ) pointed to
